Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

SUN-409 Postoperative adrenal insufficiency in patients with mild autonomous cortisol secretion
Salama, Bahaa, Hamidi, Oksana, Wang, Tracy S, Sada, Alaa, Habra, Mouhammed Amir, Dogra, Prerna, Dackiw, Alan P B, Oltmann, Sarah Catherine, Mirfakhraee, Sasan, Lingvay, Ildiko, Mckenzie, Travis, Foster, Trenton, Lyden, Melanie, Dy, Benzon, Brondani, Vânia Balderrama, Bancos, Irina, Salama, Bahaa, Hamidi, Oksana, Wang, Tracy S, Sada, Alaa, Habra, Mouhammed Amir, Dogra, Prerna, Dackiw, Alan P B, Oltmann, Sarah Catherine, Mirfakhraee, Sasan, Lingvay, Ildiko, Mckenzie, Travis, Foster, Trenton, Lyden, Melanie, Dy, Benzon, Brondani, Vânia Balderrama, Bancos, Irina

Mayo Clinic

Journal of the Endocrine Society | October 23, 2025 | Volume: 9 | Issue: Supplement_1 | Pages: No page available

10.1210/jendso/bvaf149.379 Get It

Abstract Disclosure: B. Salama: None. O. Hamidi: None. T.S. Wang: None. A. Sada: None. M.A. Habra: None. P. Dogra: None. A.P. Dackiw: None. S.C. Oltmann: None. S. Mirfakhraee: None. I. Lingvay: None. T. Mckenzie: None. T. Foster: None. M. Lyden: None. B. Dy: None. V. Balderrama Brondani: None. I. Bancos: None. Background: Patients with mild autonomous cortisol secretion (MACS) are at risk for adrenal insufficiency (AI) after unilateral adrenalectomy. Guidelines recommend initiating glucocorticoid replacement post-adrenalectomy. However, identifying patients at risk and accurately diagnosing AI can enable individualized management. Objectives: Determine the prevalence, duration and predictors of postoperative AI after unilateral adrenalectomy for MACS and compare baseline and peak cortisol post cosyntropin stimulation test (CST) In diagnosing AI. Methods: We conducted a multicenter retrospective cohort study of patients with MACS who underwent unilateral adrenalectomy and post-operative CST evaluation between January 1, 2013, and August 31, 2024. MACS was defined as cortisol >1.8 mcg/dL following overnight administration of 1 mg dexamethasone (DST-cortisol). AI was diagnosed when post-operative day 1 early morning baseline cortisol was <10 μg/dL and/or CST peak cortisol was <18 μg/dL. Baseline and peak cortisol levels were considered concordant when both met cut-offs. Biochemical (BSS) and clinical (CSS) severity scores were calculated. Results: Among 281 adults with MACS (80% women, median age 57 years, interquartile range [IQR] (47-64), the median adenoma size was 3.0 cm (IQR, 2.3-3.9), and 62 (22%) had bilateral disease. The median BSS was 4 (IQR, 3-5), and the median CSS was 6 (IQR, 2-11). Postoperative AI was diagnosed in 153 (54.5%) patients. A multivariable analysis showed that a higher BSS (OR = 1.17, 95% CI 1.01-1.36) and younger age at diagnosis (OR = 0.64, 95% CI 0.50-0.81), but not sex, BMI, or laterality, were associated with AI. Diagnosis of AI was concordant based on the baseline and peak CST cortisol cutoffs in 78% of patients. Diagnosis of AI was discordant in 22%: in 35 patients (12%), baseline cortisol was <10 μg/dL, but CST peak cortisol was ≥18 μg/dL, and in 28 cases (10%), baseline cortisol was ≥10 μg/dL, but CST peak cortisol was <18 μg/dL. Patients with bilateral MACS were more likely to have discordant results (32% vs. 19%, P < 0.001). During a median postoperative follow-up period of 15.4 months, 108 patients (70.6%) recovered from AI. The median time to recovery was 3.9 months (IQR, 3-5.9), with 41% recovering by 3 months, 60% by 6 months, and 73% by 12 months. The median time to recovery was associated with baseline BSS: mild: 3 months, moderate: 4.7 months, and severe: 14.5 months. Conclusion: We found that more than half of patients with MACS develop postoperative AI, with 50% recovering by 4 months post-surgery. BSS was associated with both the development and duration of AI. Baseline and CST peak cortisol results were concordant only in 78% of patients, thus performing both should be considered for an accurate diagnosis of AI. Presentation: Sunday, July 13, 2025
Feasibility of Symptom Burden Assessments and Early Palliative Care Integration in an Adolescent and Young Adult Leukemia Clinic
Monick, Sarah, Hanson, Collin, Hoehn, K. Sarah , Henderson, Tara O. , Daugherty, Christopher K. , Wang, Amy , Monick, Sarah E, Hlubocky, Fay J. , Stock, Wendy , DuVall, Adam , McNeer, Jennifer L.

Mayo Clinic

Journal of Adolescent and Young Adult Oncology | October 22, 2025 | Volume: 15 | Issue: 5 | Pages: 378-383

10.1177/21565333251389438 | PMID 41122915 Get It

Adolescents and young adults (AYA; ages 15–39) with acute leukemia have significant unmet supportive care needs. This pilot study integrated same-day palliative care (PC) into an AYA leukemia clinic, measuring symptom burden (SB) with validated symptom assessment tools at baseline, 3, and 6 months. Among 31 patients, moderate-severe symptoms included tiredness, anxiety, and poor appetite. AYAs experienced high SB and psychological distress, regardless of care phase or sociodemographics. With PC integration, tiredness and depression improved significantly; no symptoms worsened. Half of the PC visits led to management changes. Early integration of symptom-focused PC was feasible, value-adding, and well-received by patients.
Vascular Endothelial Growth Factor B Modulates Cardiac Functions via Ferroptosis Pathways in Post-Myocardial Infarction
Varanasi, Sai Manasa , Sabharwal, Ankit , Mukherjee, Shreyartha , Muhammad, Huzaifa, Kar, Riya, Magnano, Carter , Dorai-Raj, A., Wang, Enfeng , Dutta, Shamit K., Das, Pritam , Mukhopadhyay, Debabrata , Angom, Ramcharan Singh , Dorairaj, Anya, Dutta, Shamit, Mukhopadhyay, Debabrata , Singh Angom, Ramcharan , Mukherjee, Shreyartha , Kar, Riya, Dorairaj, Anya, Ekker, Stephen C. , Wang, Ying

Mayo Clinic

Cells | October 21, 2025 | Volume: 14 | Issue: 20 | Pages: 1642

10.3390/cells14201642 | PMID 41148858 Get It

Myocardial infarction (MI) remains a leading cause of mortality worldwide, yet effective cardioprotective strategies remain limited in clinical settings. Vascular endothelial growth factor B (VEGFB) has emerged as a promising therapeutic candidate in MI, but the role of its co-receptor, Neuropilin-1 (NRP1), in cardiomyocyte (CM) survival under ischemic stress remains poorly understood. Here, we investigated VEGFB-NRP1 signaling using an in vivo zebrafish model of cardiac injury as well as in vitro hypoxia models in CMs. We demonstrated that VEGFB overexpression conferred protection against ischemic injury and enhanced cardiac regeneration in the zebrafish heart. Mechanistically, we showed that VEGFB treatment enhances CM viability through reducing reactive oxygen species (ROS), ferroptosis activation, and preserving mitochondrial integrity. We also demonstrated that NRP1 knockdown in the CMs abolished the VEGFB-mediated protective effects, indicating the significant role of NRP1 signaling in VEGFB-induced cardioprotective effects in MI. Lastly, using transcriptome analysis, we confirmed that VEGFB induces anti-apoptotic and anti-ferroptosis gene programs in CMs in response to hypoxic stress. Collectively, our findings provide mechanistic insight into cell death activation pathways, including ferroptosis, in response to ischemic stress and further validate the therapeutic potential of VEGFB in promoting CM survival in ischemic heart disease.
International Headache society evidence-based guidelines on the use of non-invasive neuromodulation devices for the acute and preventive treatment of migraine
Yuan, Hsiangkuo , Orr, Serena L. , Al‐Karagholi, Mohammad Al‐Mahdi , Ashina, Messoud , Cohen, Fred , Diener, Hans‐Christoph , Marmura, Michael J. , Martinelli, Daniele , Matharu, Manjit , Simmonds, Lucy , Tassorelli, Cristina , Tepper, Stewart J. , Al-Karagholi, Mohammad A M , Marmura, Michael J , Martinelli, Daniele , Matharu, Manjit Singh , Petersen, Anja S , Pozo-Rosich, Patricia , Sacco, Simona , Simmonds, Lucy , Tassorelli, Cristina , Terwindt, Gisela , Wang, Shuu-Jiun , Yeh, Jiunn-Tyng , Silberstein, Stephan D , Diener, Hans-Christoph , Ashina, Messoud , Yuan, Hsiangkuo , Dodick, David W. , Jensen, Rigmor , Pozo‐Rosich, Patricia , Sacco, Simona , Terwindt, Gisela M. , Wang, Shuu‐Jiun , Silberstein, Stephen D.

Mayo Clinic

Cephalalgia | October 21, 2025 | Volume: 45 | Issue: 10 | Pages: No page available

10.1177/03331024251388377 | PMID 41117312 Get It

Objective To develop evidence-based clinical practice guidelines for non-invasive neuromodulation devices in acute and preventive migraine treatment. Methods A systematic review was conducted across six databases from 1946 to April 2025. Randomized controlled trials evaluating Food and Drug Administration-cleared or Conformité Européenne (CE)-marked non-invasive neuromodulation devices were included. The quality of evidence was assessed using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) methodology, and recommendations were developed through consensus following GRADE Evidence-to-Decision frameworks. The working group comprised 15 senior members and six junior members. Results From 1536 initial records, 15 studies met the inclusion criteria and were finally used to develop evidence-based recommendations. Evidence quality ranged from very low to moderate. Weak recommendations were issued for SAVI Dual, Cefaly, Relivion, and Nerivio in the treatment of acute migraine attacks, and for gammaCore Sapphire, Cefaly, and Nerivio in the preventive migraine treatment. Other cleared devices received no recommendations or have no eligible studies for the GRADE assessment. The primary limitations across studies included imprecision due to small sample sizes and various methodological concerns. Additionally, expert consensus recommendations were developed for devices and clinical scenarios not adequately covered by randomized controlled trials, including potential applications in pediatric populations, vestibular migraine, chronic migraine, menstrual migraine, and medication overuse headache. Conclusion Non-invasive neuromodulation devices offer promising alternatives to drug treatment for migraine management. These devices are safe and generally well tolerated and devoid of drug interactions. While current evidence quality varies, ongoing research and technological advancements show encouraging potential. Future studies should adhere to International Headache Society guidelines for neuromodulation device trials, address proper sham controls and blinding assessment, and account for patient adherence challenges in device use. Expanded insurance coverage would enhance cost-effectiveness and device accessibility. These guidelines provide a framework for clinical decision-making while highlighting areas requiring further research.
Dopaminergic Degeneration Differentially Modulates Primary Motor Cortex Activity and Motor Behavior in Hemiparkinsonian Rats
Boschen, Suelen L. , Seethaler, Julian, Wang, Shaohua , Lujan, Wendy D., Silvernail, Jodi L., White, Launia J. , Heckman, Michael G., Carter, Rickey E. , Chang, Su-Youne , Luján, J. Luis , Boschen, Suelen L , Carter, Rickey E , White, Launia J , Heckman, Michael G.

Mayo Clinic

Brain Sciences | October 20, 2025 | Volume: 15 | Issue: 10 | Pages: 1123

10.3390/brainsci15101123 | PMID 41154217 Get It

Background/Goal: Parkinson’s disease (PD) disrupts dopaminergic transmission, leading to motor deficits and altered activity in the primary motor cortex (M1). While M1 modulation is critical for motor control, its response to dopaminergic degeneration and treatment remains unclear. This study aimed to characterize M1 neuronal activity and motor behavior in hemiparkinsonian rats using in vivo calcium imaging across naïve, lesioned, and levodopa-treated states. Methods: Thirteen Sprague Dawley rats were injected with GCaMP6f in the M1 and implanted with a GRIN lens and guide cannula targeting the medial forebrain bundle. Calcium imaging and motor behavior were assessed longitudinally using a single pellet reaching test (SPRT) before and after unilateral 6-hydroxydopamine (6-OHDA) lesioning and subsequent levodopa/carbidopa treatment. Dopaminergic lesion severity was quantified via tyrosine hydroxylase immunohistochemistry. Calcium event frequency and influx were analyzed with CNMF-E and statistical modeling. Results: Levodopa treatment improved fine motor performance as shown by a significant reduction in grasp errors (mean difference: −8.91, 95% CI: −16.66 to −1.16, p = 0.031) and increased reaching duration (mean difference: 4.13, 95% CI: 0.94 to 7.32, p = 0.019) compared to the lesioned state. M1 calcium activity showed modulation dependent on lesion severity: low-lesion rats exhibited reduced event frequency (mean difference: 0.04 Hz, 95% CI: 0.001 to 0.08, p = 0.045) and increased influx post-lesion (mean difference: −0.20 z·s, 95% CI: −0.38 to −0.02, p = 0.038), while high-lesion rats showed increased influx only after levodopa treatment (mean difference: −0.34 z·s, 95% CI: −0.52 to −0.16, p = 0.003). Correlation analyses revealed that calcium influx, but not frequency, was negatively correlated with lesion severity during levodopa treatment (Spearman r = −0.857, p = 0.024). Conclusion: M1 neuronal activity appears to be differentially modulated by dopaminergic degeneration and levodopa treatment in a lesion-dependent manner. These preliminary findings suggest dynamic cortical responses in PD and support the utility of calcium imaging for monitoring circuit-level changes in disease and therapy. Further research with larger cohorts and complementary methodologies will be necessary to validate and extend these observations.
Acute Leukemias of Ambiguous Lineage With RUNX1 Mutations Show Similar Prognosis Compared to Acute Myeloid Leukemia With RUNX1 Mutations: A Study From the Bone Ma
Kirtek, Timothy , Chen, Weina , Harris, Jaryse , Bagg, Adam , Foucar, Kathryn , Tam, Wayne , Orazi, Attilio , Hasserjian, Robert P. , Wang, Sa A. , Ng, David P. , Reichard, Kaaren K. , Symes, Emily , Zhang, Xinmin , Weinberg, Olga K. , Kirtek, Timothy J , Wang, Sa A , Ng, David P , Shi, Min , Zhang, Xinmin , Arber, Daniel A , Orazi, Attilio , Hsi, Eric D. , George, Tracy I. , Arber, Daniel A.

Mayo Clinic

American Journal of Hematology | October 18, 2025 | Volume: 101 | Issue: 1 | Pages: 70-78

10.1002/ajh.70116 | PMID 41108621 Get It

ABSTRACT The World Health Organization (WHO) 5th Edition and International Consensus Classification (ICC) have continued to delineate more genetically defined acute leukemias. Both recognize genetic aberrations associated with myelodysplastic syndromes/neoplasms (MDS) as defining MDS‐related AML (AML‐MR). Mutations in RUNX1 are included in this category in the ICC, but not WHO. The current classifications are unclear on how acute leukemias with ambiguous lineage (ALAL), including those of mixed lineage (MPAL) and those without a defined lineage (AUL), should be categorized in the presence of such mutations. Our multi‐institutional study aims to determine the significance of RUNX1 mutation in ALAL compared to de novo AML. Newly diagnosed MPAL, AUL, and AML with RUNX1 mutations were collected. ALAL with MDS‐related cytogenetics, BCR::ABL1 , KMT2A rearrangements, or ZNF384 or BCL11b abnormalities were excluded. We analyzed 17 cases of ALAL and 71 cases of AML that met inclusion criteria. ALAL‐ RUNX1 and AML‐ RUNX1 showed overlapping mutational landscapes with frequent comutations in MDS‐associated genes. No ALAL‐ RUNX1 or AML‐ RUNX1 cases showed concomitant TP53 mutation. ALAL‐ RUNX1 had more bone marrow blasts and more karyotypic abnormalities; however, neither impacted survival, nor did RUNX1 variant allele frequency (VAF). Survival analysis revealed similarly poor outcomes between them. AML‐directed therapies and allogeneic hematopoietic stem cell transplant trended toward improved survival in ALAL‐ RUNX1; however, it did not reach significance. Our results suggest ALAL‐ RUNX1 is associated with younger age, higher blasts, and more karyotypic abnormalities, but has similar clinical and genetic features and outcomes to AML‐ RUNX1 . Our findings suggest, like other MR mutations, RUNX1 ‐mutated ALALs should be included within AML‐MR.
Lipid Nanoparticle-Mediated RNAi Against GIPC1 Overcomes Chemoresistance in Pancreatic Ductal Adenocarcinoma
Madamsetty, Vijay Sagar , Rachamala, Hari Krishnareddy, Dutta, Shamit K., Wang, Enfeng , Pal, Krishnendu , Mukhopadhyay, Debabrata , Dutta, Shamit Kumar, Mukhopadhyay, Debabrata , Pal, Krishnendu , Madamsetty, Vijay S

Mayo Clinic

Pharmaceutics | October 15, 2025 | Volume: 17 | Issue: 10 | Pages: 1334

10.3390/pharmaceutics17101334 | PMID 41155969 Get It

Background/Objectives: Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, characterized by aggressive tumor biology, poor vascularization, dense stromal barriers, and profound resistance to chemotherapy. GAIP-interacting protein C-terminus 1 (GIPC1), a PDZ-domain-containing adaptor protein, is highly overexpressed in PDAC and plays a critical role in tumor progression and chemoresistance. This study aimed to develop and evaluate a novel tumor-targeted liposomal siRNA delivery system (LGIPCsi) to silence GIPC1 and enhance the therapeutic efficacy of gemcitabine (GEM) in PDAC; Methods: LGIPCsi nanoparticles were synthesized and optimized for physicochemical stability, siRNA complexation efficiency, and tumor-targeting capability. Their therapeutic efficacy was assessed using in vitro pancreatic cancer cell models and in vivo orthotopic and patient-derived xenograft (PDX) models of PDAC. Biodistribution, tumor uptake, and antitumor efficacy were evaluated following systemic administration. Combination studies were performed to assess the synergistic effects of LGIPCsi and GEM; Results: GIPC1 silencing significantly sensitized pancreatic cancer cells to GEM, resulting in enhanced inhibition of tumor cell proliferation in vitro. In vivo, systemic administration of LGIPCsi achieved efficient intratumoral delivery of siGIPC1, leading to marked tumor growth suppression. Combination therapy with GEM and LGIPCsi produced synergistic antitumor effects, with substantial tumor regression compared to monotherapy groups. Importantly, no significant systemic toxicity was observed in treated animals; Conclusions: This study identifies GIPC1 as a promising therapeutic target in PDAC and demonstrates that tumor-targeted siRNA nanomedicine can effectively overcome chemoresistance when combined with standard chemotherapy. The LGIPCsi platform offers a rational and translational strategy to enhance treatment efficacy in PDAC through targeted RNAi-based combination therapy.
PEPN1924, A Phase II Study of Trastuzumab Deruxtecan in Patients With Recurrent Human Epidermal Growth Factor Receptor 2+ Osteosarcoma: A Children's Oncology Group Pediatric Early-Phase Clinical Trial Network Study
Reed, Damon R. , Janeway, Katherine A. , Hall, David , Crompton, Brian D. , Wang, Wei‐Lien , Zylber, Rebecca, Contreras, Alejandro , Carrero, Giselle, Voss, Stephan D. , Militano, Olga, Pickett, Cheryl A., Fox, Elizabeth , Weigel, Brenda J. , Teachey, David T , Crompton, Brian D , Lazar, Alexander J , Wang, Wei-Lien , Contreras, Alejandro , Voss, Stephan D , Reid, Joel M , Safgren, Stephanie L , Gorlick, Richard , Fox, Elizabeth , Weigel, Brenda J , Reed, Damon R , Minard, Charles G. , Lazar, Alexander J. , Reid, Joel M. , Safgren, Stephanie L. , Görlick, Richard

Mayo Clinic

JCO Oncology Advances | October 14, 2025 | Volume: No volume available | Issue: 2 | Pages: No page available

10.1200/oa-25-00094 | PMID 42131734 Get It

PURPOSE Human epidermal growth factor receptor 2 (HER2), a transmembrane receptor with kinase activity involved in cell signaling through the RAS pathway, is expressed in osteosarcoma (OST). Trastuzumab deruxtecan (T-DXd) is an antibody-drug conjugate with a HER2-targeting monoclonal antibody, trastuzumab, linked to a topoisomerase I inhibitor. We report results of a phase II study of T-DXd in adolescents and young adults with HER2-positive relapsed, unresectable OST (ClinicalTrials.gov identifier: NCT04616560 ). METHODS Patients age 12-39 years with relapsed, unresectable OST were eligible for centrally evaluated HER2 expression screening by immunohistochemistry. Patients with >10% of OST cells with cytoplasmic or membranous HER2 expression of any intensity were eligible to receive T-DXd at 5.4 mg/kg intravenously once every 3 weeks for up to 2 years. The study used a 9 + 15 Simon's optimal two-stage design with a primary end point of event-free survival at 24 weeks. RESULTS Fifty patients were screened for HER2, and 41 met the inclusion criteria of 10% of OST cells having membranous or cytoplasmic HER2 expression. Nine eligible patients, two younger than 18 years, were enrolled and received T-DXd. With a single patient having more than 24 weeks of stable disease (SD) of the nine planned in the first stage, this study did not meet criteria to progress to stage II. The estimated SD rate at 24 weeks is 11.1%. The median (range) number of cycles of therapy was 2 (2-12). Grade 3 and 4 possibly related adverse events occurred in three of nine patients and included nausea, vomiting, tumor hemorrhage, cytopenias (n = 3), wound infection, and hypertension. CONCLUSION T-DXd did not demonstrate sufficient activity to expand enrollment to the planned second stage in patients with OST. No new safety signals were observed.
Incarceration and Quality of Cancer Care
Aminawung, Jenerius A. , Weinstein, Jason , Puglisi, Lisa B. , Mehta, Rajni , Lin, Hsiu‐Ju , Wang, Emily A. , Gross, Cary P. , Oladeru, Oluwadamilola T. , Richman, Ilana B.

Mayo Clinic

JAMA Network Open | October 14, 2025 | Volume: 8 | Issue: 10 | Pages: e2537400

10.1001/jamanetworkopen.2025.37400 | PMID 41085984 Get It

ImportanceAlthough incarceration is associated with worse cancer outcomes, little is known about quality of cancer care among people with a history of incarceration.ObjectiveTo describe quality of cancer care among those diagnosed with cancer during or immediately after incarceration.Design, Setting, and ParticipantsThis longitudinal cohort study used Connecticut Tumor Registry data linked to Department of Correction rosters from 2005 through 2016. Patients diagnosed with cancer while incarcerated were matched to those diagnosed within 12 months after incarceration and to those with no history of incarceration. Analysis was performed between March 2024 and January 2025.ExposuresIncarceration status at time of cancer diagnosis.Main Outcomes and MeasuresThe main outcomes were treatment initiation within 60 days and receipt of recommended pretreatment and therapeutic care, ascertained from medical records and tumor registries. Logistic regression was used to evaluate odds of treatment initiation by 60 days. The proportion of recommended elements of pretreatment and therapeutic care received was calculated, and group differences were assessed using χ2 tests.ResultsThe sample included 690 individuals (233 diagnosed during incarceration, 221 diagnosed within 12 months after incarceration, and 236 with no incarceration history). The mean (SD) age was 49.7 (12.1) years, and 611 (88.6%) were male. Compared with those with no history of incarceration, those diagnosed with cancer during incarceration were less likely to initiate treatment within 60 days (169 of 209 [80.9%] vs 131 of 189 [69.3%]; OR, 0.49 [95% CI, 0.31-0.79]). Initiation of treatment within 60 days was not statistically different for those diagnosed after incarceration vs those with no history of incarceration (144 of 187 [77.0%]; OR, 0.81 [95% CI, 0.49-1.34]). Those diagnosed with local and regional cancers during incarceration received 49.2% of recommended treatment-related care (31 of 63 measures), while those diagnosed after incarceration received 45.3% (34 of 75 measures), compared with 66.7% (36 of 54 measures) among those with no history of incarceration (P < .001). People diagnosed with local and regional cancers during incarceration received 80.6% of recommended pretreatment evaluation (54 of 67 measures), and those diagnosed after received 96.8% (59 of 68 measures), compared with 78.1% (50 of 64 measures) among those with no history of incarceration (P = .01).Conclusions and RelevanceIn this cohort study of people with a history of incarceration, incarceration was associated with lower likelihood of receiving timely, high-quality cancer treatment. Along with other published literature, this work suggests that gaps in quality of care may contribute to observed disparities in outcomes.
In Reply: Are There Differences in 2-Year Outcomes Between 2-Level Anterior Cervical Diskectomy and Fusion Versus Single-Level Anterior Cervical Corpectomy and Fusion to Treat Cervical Myelopathy? A Quality Outcomes Database Study
Berlin, Connor , Mummaneni, Praveen V., Chan, Andrew K. , Chou, Dean , Fu, Kai-Ming, Bydon, Mohamad , Bisson, Erica F. , Shaffrey, Christopher I. , Gottfried, Oren N., Asher, Anthony L. , Coric, Domagoj , Potts, Eric A. , Foley, Kevin T. , Wang, Michael Y. , Virk, Michael S. , Knightly, John J. , Meyer, Scott A., Upadhyaya, Cheerag D., Tumialán, Luis M. , Turner, Jay D. , Uribe, Juan S. , Haid, Regis W., Yen, Chun-Po , Shaffrey, Mark E., Ibrahim, Sufyan , Mummaneni, Praveen V. , Park, Paul

Mayo Clinic

Neurosurgery | October 14, 2025 | Volume: 97 | Issue: 6 | Pages: e177-e178

10.1227/neu.0000000000003811 | PMID 41085387 Get It